Biomarkers and prognostic factors for mesothelioma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

17 citing papers in PubMed.

1. Candidate biomarkers to identify mesothelioma patients at risk of developing venous thromboembolism post-surgery.Scientific reports · 2026
   Article
2. The Mesothelioma Systemic Inflammation Score Is Independently Associated with Overall Survival and Predicts Benefit of Multimodality Treatment in Pleural Mesothelioma.Cancers · 2025
   Article
3. An Evaluation Into the Robustness of Grading of Pleural Mesothelioma Outside of Specialist Centres.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2025
   Article
4. Pan-cancer analysis of cuproptosis-promoting gene signature from multiple perspectives.Clinical and experimental medicine · 2023
   Article
5. PD-L1 expression complements CALGB prognostic scoring system in malignant pleural mesothelioma.Frontiers in oncology · 2023
   Article
6. Malignant pleural mesothelioma: clinical experience and prognostic value of derived neutrophil-to-lymphocyte ratio and PD-L1 expression.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021
   Observational
7. Elevated Serum Megakaryocyte Potentiating Factor as a Predictor of Poor Survival in Patients with Mesothelioma and Primary Lung Cancer.The journal of applied laboratory medicine · 2018
   Article
8. Genomics and Epigenetics of Malignant Mesothelioma.High-throughput · 2018
   Review
9. A Novel Panel of Serum Biomarkers for MPM Diagnosis.Disease markers · 2017
   Article
10. Management of malignant pleural mesothelioma - part 1: epidemiology, diagnosis, and staging : Consensus of the Austrian Mesothelioma Interest Group (AMIG).Wiener klinische Wochenschrift · 2016
    Article
11. MicroRNA‑21 regulates the expression of BTG2 in HepG2 liver cancer cells.Molecular medicine reports · 2015
    Article
12. Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2015
    Article
13. MiR-score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma.Molecular oncology · 2015
    Article
14. Reproducibility of histological subtyping of malignant pleural mesothelioma.Virchows Archiv : an international journal of pathology · 2014
    Article
15. Supplementary prognostic variables for pleural mesothelioma: a report from the IASLC staging committee.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2014
    Article
16. Expression and significance of miRNA-21 and BTG2 in lung cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013
    Article
17. The challenge of prognostic markers in pleural mesothelioma.Journal of thoracic disease · 2013
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.